Paper36214865
Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives.
Tuli HS and 12 others. Naunyn Schmiedebergs Arch Pharmacol, 2023. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives. Papers, record 36214865. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36214865
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives.
- PubMed
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Flavonoids | Major topic |
| Antineoplastic Agents | Major topic |
| Signal Transduction | |
| Cell Line, Tumor |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 38619590 | Correction: Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives. | https://conductscience.org/library/papers/38619590 |
Source PubMed
References136
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16321545 | A review on pro- and anti-angiogenic factors as targets of clinical intervention. | Pharmacol Res | 2006 | https://conductscience.org/library/papers/16321545 | PubMed |
| 2 | 35480139 | Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures. | Biomed Res Int | 2022 | https://conductscience.org/library/papers/35480139 | PubMed |
| 3 | 24634660 | Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. | Front Physiol | 2014 | https://conductscience.org/library/papers/24634660 | PubMed |
| 4 | 15036470 | Cytotoxic activities of flavonoids from two Scutellaria plants in Chinese medicine. | J Ethnopharmacol | 2004 | https://conductscience.org/library/papers/15036470 | PubMed |
| 5 | 22155252 | A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo. | Biochem Biophys Res Commun | 2012 | https://conductscience.org/library/papers/22155252 | PubMed |
| 6 | 25304218 | Natural product inhibitors of ocular angiogenesis. | Exp Eye Res | 2014 | https://conductscience.org/library/papers/25304218 | PubMed |
| 7 | 31402703 | An unambiguous and practical synthesis of Oroxylin A: a commonly misidentified flavone. | Nat Prod Res | 2021 | https://conductscience.org/library/papers/31402703 | PubMed |
| 8 | 8701285 | Fighting cancer by attacking its blood supply. | Sci Am | 1996 | https://conductscience.org/library/papers/8701285 | PubMed |
| 9 | 28938606 | Oroxylin A inhibits colitis by inactivating NLRP3 inflammasome. | Oncotarget | 2017 | https://conductscience.org/library/papers/28938606 | PubMed |
| 10 | 20411407 | Use of isoform-specific UGT metabolism to determine and describe rates and profiles of glucuronidation of wogonin and oroxylin A by human liver and intestinal microsomes. | Pharm Res | 2010 | https://conductscience.org/library/papers/20411407 | PubMed |
| 11 | 28726775 | Oroxylin A activates PKM1/HNF4 alpha to induce hepatoma differentiation and block cancer progression. | Cell Death Dis | 2017 | https://conductscience.org/library/papers/28726775 | PubMed |
| 12 | 19626645 | Involvement of p53 in oroxylin A-induced apoptosis in cancer cells. | Mol Carcinog | 2009 | https://conductscience.org/library/papers/19626645 | PubMed |
| 13 | 34117368 | Oroxylin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression. | Acta Pharmacol Sin | 2022 | https://conductscience.org/library/papers/34117368 | PubMed |
| 14 | 34656666 | Ethnodermatological use of medicinal plants in India: From ayurvedic formulations to clinical perspectives - A review. | J Ethnopharmacol | 2022 | https://conductscience.org/library/papers/34656666 | PubMed |
| 15 | 30318784 | Oroxylin A inhibits Kaposi's sarcoma-associated herpes virus (KSHV) vIL-6-mediated lymphatic reprogramming of vascular endothelial cells through modulating PPARγ/Prox1 axis. | J Med Virol | 2019 | https://conductscience.org/library/papers/30318784 | PubMed |
| 16 | 25218897 | Oroxylin A enhances memory consolidation through the brain-derived neurotrophic factor in mice. | Brain Res Bull | 2014 | https://conductscience.org/library/papers/25218897 | PubMed |
| 17 | 23934681 | Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARγ and RXRα. | Int J Cancer | 2014 | https://conductscience.org/library/papers/23934681 | PubMed |
| 18 | 31927013 | Pharmacokinetics, tissue distribution and excretion study of Oroxylin A, Oroxylin A 7-O-glucuronide and Oroxylin A sodium sulfonate in rats after administration of Oroxylin A. | Fitoterapia | 2020 | https://conductscience.org/library/papers/31927013 | PubMed |
| 19 | 32999161 | Oroxylin A Exerts Its Antitumor Effects in Human Gallbladder Cancer via Inhibition of the PTEN/PI3K/AKT Signaling Pathway. | Biol Pharm Bull | 2020 | https://conductscience.org/library/papers/32999161 | PubMed |
| 20 | 18828708 | Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. | Antioxid Redox Signal | 2009 | https://conductscience.org/library/papers/18828708 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41049034 | Deciphering the Role of Oroxylin A in Liver Fibrosis. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/41049034 | PubMed |
| 41032091 | Oroxylin A exerts antiproliferative effects through downregulation of E6 and E7 oncogenes in cervical cancer HeLa cells. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/41032091 | PubMed |
| 40211010 | Oroxylin A may promote cell apoptosis and inhibit epithelial-mesenchymal transition in endometrial cancer, associated with the ERβ/PI3K/AKT pathway. | Sci Rep | 2025 | https://conductscience.org/library/papers/40211010 | PubMed |
| 39834817 | An updated review summarizing the anticancer potential of flavonoids via targeting NF-kB pathway. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39834817 | PubMed |
| 39804528 | Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research. | Mol Neurobiol | 2025 | https://conductscience.org/library/papers/39804528 | PubMed |
| 38730663 | The Role of Phytonutrient Kaempferol in the Prevention of Gastrointestinal Cancers: Recent Trends and Future Perspectives. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38730663 | PubMed |
| 36840363 | Nano-biotechnology in tumour and cancerous disease: A perspective review. | J Cell Mol Med | 2023 | https://conductscience.org/library/papers/36840363 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36214865
GET https://conductscience.org/api/papers/v1/36214865/references?page=2